The diagnosis and management of Kawasaki disease
J Royle
Department of General Medicine, Royal Children's Hospital, Melbourne
Search for more papers by this authorD Burgner
School of Paediatrics and Child Health, University of Western Australia, and Princess Margaret Hospital, Perth, Western Australia
Search for more papers by this authorN Curtis
Department of Paediatrics, University of Melbourne, and Paediatric Infectious Diseases Unit, Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorJ Royle
Department of General Medicine, Royal Children's Hospital, Melbourne
Search for more papers by this authorD Burgner
School of Paediatrics and Child Health, University of Western Australia, and Princess Margaret Hospital, Perth, Western Australia
Search for more papers by this authorN Curtis
Department of Paediatrics, University of Melbourne, and Paediatric Infectious Diseases Unit, Department of General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia
Search for more papers by this authorAbstract
Abstract: Kawasaki disease (KD) is a systemic vasculitis of childhood with a predilection for the coronary arteries. It is the predominant cause of paediatric acquired heart disease in developed countries. The aetiology of KD remains unknown and consequently there is no diagnostic test. The diagnosis is made using a constellation of clinical criteria that in isolation have poor sensitivity and specificity. Early treatment prevents overt coronary artery damage in the majority of children. The long-term effects of childhood KD on later cardiovascular health remain unknown. A recent study showed that treatment of KD in Australia is suboptimal, with late diagnosis occurring in approximately half of the cases and an unacceptably high incidence of acute cardiac involvement. These guidelines highlight the difficulties in the diagnosis of KD and offer some clues that may assist early recognition of this important paediatric disease. They also detail current treatment recommendations and the evidence on which they are based. Increased awareness of the epidemiology and spectrum of the clinical presentation of KD is essential for early recognition and optimal management.
REFERENCES
- 1 Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children (Japanese). Jpn. J. Allergy 1967; 16: 178–222.
- 2 Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med. 1986; 315: 341–7.
- 3 Nagashima M, Matsushima M, Matsuoka H, Ogawa A, Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. J. Pediatr. 1987; 110: 710–12.
- 4 Newburger JW, Fulton DR. Kawasaki disease. Curr. Opin. Pediatr. 2004; 16: 508–14.
- 5 Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur. J. Pediatr. 2004; 163: 285–91.
- 6 Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533–44.
- 7 Rowley AH, Shulman ST. Kawasaki syndrome. Clin. Microbiol. Rev. 1998; 11: 405–14.
- 8 Curtis N. What is the cause of Kawasaki disease? Curr. Med. Lit. Inf. Dis. 1994; 8: 71–6.
- 9 Rowley AH. The etiology of Kawasaki disease: superantigen or conventional antigen? Pediatr. Infect. Dis. J. 1999; 18: 69–70.
- 10 Meissner HC, Leung DY. Superantigens, conventional antigens and the etiology of Kawasaki syndrome. Pediatr. Infect. Dis. J. 2000; 19: 91–4.
- 11 Lloyd AJ, Walker C, Wilkinso M. Kawasaki disease: is it caused by an infectious agent? Br. J. Biomed. Sci. 2001; 58: 122–8.
- 12 Royle JA, Williams K, Elliott E et al. Kawasaki disease in Australia, 1993–95. Arch. Dis. Child. 1998; 78: 33–9.
- 13 Dhillon R, Newton L, Rudd PT, Hall SM. Management of Kawasaki disease in the British Isles. Arch. Dis. Child. 1993; 69: 631–6; discussion 637–8.
- 14 Taubert KA, Rowley AH, Shulman ST. A 10 year (1984–1993) United States hospital survey of Kawasaki disease. In: H Kato, ed. Kawasaki Disease. Amsterdam : Elsevier Science, 1993; 34–8.
- 15 Park YW, Park IS, Kim CH et al. Epidemiologic study of Kawasaki disease in Korea, 1997–1999: comparison with previous studies during 1991–1996. J. Korean Med. Sci. 2002; 17: 453–6.
- 16 Yanagawa H, Nakamura Y, Yashiro M et al. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics 1998; 102: E65.
- 17 Burns JC, Kushner HI, Bastian JF et al. Kawasaki disease: a brief history. Pediatrics 2000; 106: E27.
- 18 Tsuchida S, Yamanaka T, Tsuchida R, Nakamura Y, Yashiro M, Yanagawa H. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta. Paediatr. 1996; 85: 995–7.
- 19 Iwata F, Hanawa Y, Takashima H, Shimoura K, Nishibayashi Y. Kawasaki disease in a father and son. Acta. Paediatr. Jpn. 1992; 34: 84–6.
- 20 Rauch AM. Kawasaki syndrome. critical review of U.S. epidemiology. Prog. Clin. Biol. Res. 1987; 250: 33–44.
- 21 Fujita Y, Nakamura Y, Sakata K et al. Kawasaki disease in families. Pediatrics 1989; 84: 666–9.
- 22 Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch. Pediatr. Adolesc. Med. 1995; 149: 779–83.
- 23 Nakamura Y, Yanagawa H, Kato H, Harada K, Kawasaki T. Mortality among patients with a history of Kawasaki disease: the third look. The Kawasaki Disease Follow-up Group. Acta. Paediatr. Jpn. 1998; 40: 419–23.
- 24 Nakamura Y, Yanagawa H, Harada K, Kato H, Kawasaki T. Mortality among persons with a history of Kawasaki disease in Japan: existence of cardiac sequelae elevated the mortality. J. Epidemiol. 2000; 10: 372–5.
- 25 Fulton DR, Newburger JW. Long-term cardiac sequelae of Kawasaki disease. Curr. Rheumatol. Rep. 2000; 2: 324–9.
- 26 Kato H, Sugimura T, Akagi T et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379–85.
- 27 Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997; 100: 695–9.
- 28 Naoe S, Takahashi K, Masuda H, Tanaka N. Coronary findings post Kawasaki disease in children who died of other causes. Prog. Clin. Biol. Res. 1987; 250: 341–6.
- 29 Dhillon R, Clarkson P, Donald AE et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103–6.
- 30 Deng YB, Xiang HJ, Chang Q, Li CL. Evaluation by high-resolution ultrasonography of endothelial function in brachial artery after Kawasaki disease and the effects of intravenous administration of vitamin C. Circ. J. 2002; 66: 908–12.
- 31 Sugimura T, Kato H, Inoue O, Takagi J, Fukuda T, Sato N. Vasodilatory response of the coronary arteries after Kawasaki disease: evaluation by intracoronary injection of isosorbide dinitrate. J. Pediatr. 1992; 121: 684–8.
- 32 Noto N, Okada T, Yamasuge M et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001; 107: 1095–9.
- 33 Dahdah NS, Fournier A, Jaeggi E et al. Segmental myocardial contractility versus perfusion in Kawasaki disease with coronary arterial aneurysm. Am. J. Cardiol. 1999; 83: 48–51.
- 34 Silva AA, Maeno Y, Hashmi A, Smallhorn JF, Silverman ED, McCrindle BW. Cardiovascular risk factors after Kawasaki disease: a case-control study. J. Pediatr. 2001; 138: 400–5.
- 35 Iemura M, Ishii M, Sugimura T, Akagi T, Kato H. Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and function. Heart 2000; 83: 307–11.
- 36 Takahashi K, Oharaseki T, Naoe S. Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr. Cardiol. 2001; 22: 138–42.
- 37 Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr. Infect. Dis. J. 1990; 9: 122–6.
- 38 Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associated with Kawasaki syndrome. Pediatr. Infect. Dis. 1985; 4: 258–61.
- 39 Burns JC, Mason WH, Glode MP et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J. Pediatr. 1991; 118: 680–6.
- 40 Chao SM, Phua KB. Perineal eruption as an early sign of Kawasaki disease. Ann. Acad. Med. Singapore 1991; 20: 244–7.
- 41 Stamos JK, Corydon K, Donaldson J, Shulman ST. Lymphadenitis as the dominant manifestation of Kawasaki disease. Pediatrics 1994; 93: 525–8.
- 42 Burgner D, Festa M, Isaacs D. Delayed diagnosis of Kawasaki disease presenting with massive lymphadenopathy and airway obstruction. BMJ 1996; 312: 1471–2.
- 43 Fan PC, Chiu CH, Yen MH, Huang YC, Li CC, Lin TY. School-aged children with Kawasaki disease: high incidence of cervical lymphadenopathy and coronary artery involvement. J. Paediatr. Child Health 2003; 39: 55–7.
- 44 Dengler LD, Capparelli EV, Bastian JF et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. Pediatr. Infect. Dis. J. 1998; 17: 478–81.
- 45 Falcini F, Cimaz R, Calabri GB et al. Kawasaki's disease in northern Italy: a multicenter retrospective study of 250 patients. Clin. Exp. Rheumatol. 2002; 20: 421–6.
- 46 Barton LL, Luisiri A, Dawson JE. Hydrops of the gallbladder in childhood infections. Pediatr. Infect. Dis. J. 1995; 14: 163–4.
- 47 Ohta K, Seno A, Shintani N et al. Increased levels of urinary interleukin-6 in Kawasaki disease. Eur. J. Pediatr. 1993; 152: 647–9.
- 48 Kuniyuki S, Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J. Am. Acad. Dermatol. 1997; 37: 303–4.
- 49 Sireci G, Dieli F, Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol. Med. 2000; 6: 581–90.
- 50 Bolz D, Arbenz U, Fanconi S, Bauersfeld U. Myocarditis and coronary dilatation in the 1st week of life: neonatal incomplete Kawasaki disease? Eur. J. Pediatr. 1998; 157: 589–91.
- 51 Dahlem PG, Von Rosenstiel IA, Lam J, Kuijpers TW. Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. Intensive Care Med. 1999; 25: 1137–9.
- 52 Tomita S, Chung K, Mas M, Gidding S, Shulman ST. Peripheral gangrene associated with Kawasaki disease. Clin. Infect. Dis. 1992; 14: 121–6.
- 53 Witt MT, Minich LL, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics 1999; 104: e10.
- 54 Stapp J, Marshall GS. Fulfillment of diagnostic criteria in Kawasaki disease. Southern Med. J. 2000; 93: 44–7.
- 55 Barone SR, Pontrelli LR, Krilov LR. The differentiation of classic Kawasaki disease, atypical Kawasaki disease, and acute adenoviral infection: use of clinical features and a rapid direct fluorescent antigen test. Arch. Pediatr. Adolesc. Med. 2000; 154: 453–6.
- 56 Newburger JW. Kawasaki disease: who is at risk? J. Pediatr. 2000; 137: 149–52.
- 57 Burns JC, Wiggins JW Jr, Toews WH et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J. Pediatr. 1986; 109: 759–63.
- 58 Joffe A, Kabani A, Jadavji T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J. Med. 1995; 162: 322–7.
- 59 Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than 1 year of age. J. Pediatr. 1995; 126: 524–9.
- 59a Newburger JW, Takahashi M, Gerber MA, Gewitz, MH, Tani LY, Burns, JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Committee of Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committe on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708–33.
- 60 Curtis N. Kawasaki disease. BMJ 1997; 315: 322–3.
- 61 Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J. Pediatr. 1986; 108: 388–92.
- 62 Koyanagi H, Yanagawa H, Nakamura Y, Yashiro M. Serum C-reactive protein levels in patients with Kawasaki disease: from the results of nation-wide surveys of Kawasaki disease in Japan. Acta. Paediatr. 1997; 86: 613–19.
- 63 Terai M, Yasukawa K, Honda T et al. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr. Infect. Dis. J. 2002; 21: 777–81.
- 64 Venglarcik JS III, Ayas M, Woods T. Severe thrombocytopenia as a presenting manifestation of Kawasaki disease. Arch. Pediatr. Adolesc. Med. 1995; 149: 215–17.
- 65 Ting EC, Capparelli EV, Billman GF, Lavine JE, Matsubara T, Burns JC. Elevated gamma-glutamyltransferase concentrations in patients with acute Kawasaki disease. Pediatr. Infect. Dis. J. 1998; 17: 431–2.
- 66 Ohno T, Yuge T, Kariyazono H et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur. J. Pediatr. 2002; 161: 105–11.
- 67 Koyanagi H, Nakamura Y, Yanagawa H. Lower level of serum potassium and higher level of C-reactive protein as an independent risk factor for giant aneurysms in Kawasaki disease. Acta. Paediatr. 1998; 87: 32–6.
- 68 Scott JS, Ettedgui JA, Neches WH. Cost-effective use of echocardiography in children with Kawasaki disease. Pediatrics 1999; 104: e57.
- 69 Burns JC. Kawasaki disease. Adv. Pediatr. 2001; 48: 157–77.
- 70 Tse SM, Silverman ED, McCrindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J. Pediatr. 2002; 140: 450–5.
- 71 Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057–61.
- 72 Fong NC, Hui YW, Li CK, Chiu MC. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr. Cardiol. 2004; 25: 31–4.
- 73 Muta H, Ishii M, Egami K et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J. Pediatr. 2004; 144: 496–9.
- 74 Xu C, Poirier B, Van Huyen JP et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am. J. Pathol. 1998; 153: 1257–66.
- 75 Leung DY. The immunologic effects of IVIG in Kawasaki disease. Int. Rev. Immunol. 1989; 5: 197–202.
- 76 Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991; 324: 1633–9.
- 77 Newburger JW. Treatment of Kawasaki disease. Lancet 1996; 347: 1128.
- 78 Brogan PA, Bose A, Burgner D et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch. Dis. Child. 2002; 86: 286–90.
- 79 Laupland KB, Dele Davies H. Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr. Cardiol. 1999; 20: 177–83.
- 80 Nakashima L, Edwards DL. Treatment of Kawasaki disease. Clin. Pharm. 1990; 9: 755–62.
- 81 Lang B, Duffy CM. Controversies in the management of Kawasaki disease. Best Pract. Res. Clin. Rheumatol. 2002; 16: 427–42.
- 81a Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114: e689–93.
- 82 Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J. Pediatr. 1997; 131: 888–93.
- 83 Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J. Pediatr. 1996; 128: 701–3.
- 84 The Royal College of General Practitioners. Guidelines for the Management of Kawasaki Disease. 1997. Available from URL: http://www.rcgp.org.uk/news/rcn0009.htm.
- 85 Shackelford PG, Strauss AW. Kawasaki syndrome. N. Engl. J. Med. 1991; 324: 1664–6.
- 86 Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J. Pediatr. 1993; 123: 657–9.
- 87 Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch. Pediatr. Adolesc. Med. 2000; 154: 694–9.
- 88 Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000; 105: E78.
- 89 Miura M, Ohki H, Tsuchihashi T et al. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Arch. Dis. Child 2004; 89: 776–80.
- 90 Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr. Infect. Dis. J. 2004; 23: 463–4.
- 91 Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175–9.
- 92 Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J. Pediatr. 1996; 128: 146–9.
- 93 Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J. Pediatr. 1999; 135: 411–13.
- 94 Al-Mayouf SM. The use of corticosteroid therapy in refractory Kawasaki patients. Clin. Rheumatol. 2004; 23: 11–13.
- 95 Hung JJ, Chiu CH. Pulse methylprednisolone therapy in the treatment of immune globulin-resistant Kawasaki disease: case report and review of the literature. Ann. Trop. Paediatr. 2004; 24: 89–93.
- 96 Sundel RP. Update on the treatment of kawasaki disease in childhood. Curr. Rheumatol. Rep. 2002; 4: 474–82.
- 97 Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J. Pediatr. 2003; 142: 611–16.
- 98 Shulman ST. Is there a role for corticosteroids in Kawasaki disease? J. Pediatr. 2003; 142: 601–3.
- 99 Jibiki T, Terai M, Kurosaki T et al. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Eur. J. Pediatr. 2004; 163: 229–33.
- 100 Nakamura Y, Yanagawa H. A case-control study of recurrent Kawasaki disease using the database of the nationwide surveys in Japan. Eur. J. Pediatr. 1996; 155: 303–7.
- 101 Michie C, Kinsler V, Tulloh R, Davidson S. Recurrent skin peeling following Kawasaki disease. Arch. Dis. Child. 2000; 83: 353–5.
- 102 Matsuoka S, Tatara K, Nakagawa R, Mori K, Kuroda Y. Tendency toward atopy in Kawasaki disease. Eur. J. Pediatr. 1997; 156: 30–2.
- 103 Brosius CL, Newburger JW, Burns JC, Hojnowski-Diaz P, Zierler S, Leung DY. Increased prevalence of atopic dermatitis in Kawasaki disease. Pediatr. Infect. Dis. J. 1988; 7: 863–6.
- 104 King WJ, Schlieper A, Birdi N, Cappelli M, Korneluk Y, Rowe PC. The effect of Kawasaki disease on cognition and behavior. Arch. Pediatr. Adolesc. Med. 2000; 154: 463–8.
- 105 National Health and Medical Research Council (NHMRC). Australian Immunisation Handbook, 8th edn. Canberra : Commonwealth Department of Health and Ageing, 2003.
- 106 Centres for Disease Control and Prevention (CDC). Recommended childhood immunization schedule – United States, 1998. MMWR Morb Mortal Wkly Rep 1998; 47: 8–12.
- 107 Miura M, Katada Y, Ishihara J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. Eur. J. Pediatr. 2004; 163: 25–9.
- 108 American Academy of Pediatrics. Kawasaki disease. In: LK Pickering, ed. Red Book. Report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village , IL : American Academy of Pediatrics, 2003; 395.
- 109 Sugimura T, Kato H, Inoue O et al. Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994, 1995; 89: 258–65.
- 110 H Kato, ed. Wall Abnormality of Apparently Normal Coronary Artery After KD. From KD. 5th International Kawasaki Disease Symposium. Japan : Fukuoka, 1995.
- 111 Suzuki A, Yamagishi M, Kimura K et al. Functional behavior and morphology of the coronary artery wall in patients with Kawasaki disease assessed by intravascular ultrasound. J. Am. Coll. Cardiol. 1996; 27: 291–6.